The use of percent free prostate specific antigen for staging clinically localized prostate cancer

Journal of Urology

Volumn 159, Issue 4, 1998, Pages 1238-1242

  Pannek, Jürgen ^a   Rittenhouse, Harry G ^a   Chan, Daniel W ^a   Epstein, Jonathan I ^a   Walsh, Patrick C ^a   Partin, Alan W ^a  

^a NONE

Author keywords

Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE;

EID: 0031921732     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63571-7     Document Type: Article

References (33)

1. Partin, A. W. and Oesterling, J. E.: The clinical usefulness of prostate specific antigen: update 1994. J. Urol., 152: 1358, 1994.
2. Brawer, M. K. and Lange, P. H.: Prostate specific antigen: its role in early detection, staging and monitoring of prostatic carcinoma. J. Endourol., 3: 227, 1989.
3. Partin, A. W., Carter, H. B., Chan, D. W., Epstein, J. I., Oesterling, J. E., Rock, R. C., Weber, J. P. and Walsh, P. C.: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol., 143: 747, 1990.
4. Catalona, W. J., Smith, D. S., Wolfert, R. L., Wang, T. J., Rittenhouse, H. G., Ratliff, T. L. and Nadler, R. B.: Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening, J.A.M.A., 274: 1214, 1995.
5. Luderer, A. A., Chen, Y. T., Soriano, T. F., Kramp, W. J., Carlson, G., Cuny, C., Sharp, T., Smith, W. Petteway, J., Brawer, M. K. and Thiel, R.: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology, 46: 187, 1995.
6. Partin, A. W. and Carter, H. B.: The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer. Urol. Clin. N. Amer., 23: 531, 1996.
7. Partin, A. W., Catalona, W. J., Southwick, P. C., Subong, E. N. P., Gasior, G. H. and Chan, D. W.: Analysis of percent free prostate specific antigen for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology, suppl., 48: 55, 1996.
8. Prestigiacomo, A. F., Lilja, H., Pettersson, K., Wolfert, R. L. and Stamey, T. A.: A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J. Urol., 156: 350, 1996.
9. Chen, Y. T., Luderer, A. A., Thiel, R. P., Carlson, G., Cuny, C. L. and Soriano, T. F.: Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology, 47: 518, 1996.
10. Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I. and Walsh, P. C.: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol. Clin. N. Amer., 20: 713, 1993.
11. Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I. and Walsh, P. C.: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 150: 110, 1993.
12. Partin, A. W., Kattan, M. W., Subong, E. N., Walsh, P. C., Wojno, K. J., Oesterling, J. E., Scardino, P. T. and Pearson, J. D.: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. J.A.M.A., 277: 1445, 1997.
13. Pannek, J., Subong, E. N. P., Jones, K., Marschke, P. L. S., Epstein, J. I., Chan, D. W., Carter, H. B., Luderer, A. A. and Partin, A. W.: The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. Urology, suppl., 48: 51, 1996.
14. Graefen, M., Hammerer, P., Henke, P., Hilz, H., Huland, E. and Huland, H.: Percentage of free PSA does not correlate with pathological outcome. J. Urol., part 2, 155: 370A, abstract 237, 1996.
15. Arcangeli, C. G., Shepherd, D. L., Smith, D. S., Humphrey, P. A., Keetch, D. W. and Catalona, W. J.: Correlation of percent free PSA with pathologic features of prostatic carcinomas. J. Urol., part 2, 155: 415A, abstract 420, 1996.
16. Elgamal, A. A., Cornillie, F. J., van Poppel, H. P., van de Voorde, W. M., McCabe, R. and Baert, L. V.: Free-to-total prostate specific antigen ratio as a single test for detection of significant stage Tic prostate cancer. J. Urol., 156: 1042, 1996.
17. Henricks, W. H., England, B. G., Giacherio, D. A., Oesterling, J. E. and Wojno, K. J.: Free to total PSA ratio does not predict extraprostatic spread of prostatic adenocarcinoma, J. Urol., part 2, 155: 369A, abstract 236, 1996.
18. Bangma, C. H., Kranse, R., Blijenberg, B. G. and Schröder, F. H.: The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. J. Urol., 157: 544, 1997.
19. Lerner, S. E., Jacobsen, S. J., Lilja, H., Bergstralh, E. J., Ransom, J., Klee, G. G., Piironen, T., Blute, M. L., Lieber, M. M., Zincke, H., Pettersson, K., Peterson, D. and Oesterling, J. E.: Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology, 48: 240, 1996.
20. Woodrum, D. L., French, C. M., Hill, T. M., Roman, S. J., Slatore, H. L., Shaffer, J. L., York, L. G., Eure, K. L., Loveland, K. G., Gasior, G. H., Southwick, P. C. and Shamel, L. B.: Analytical performance of the Tandem®-R free PSA immunoassay measuring free prostate-specific antigen. Clin. Chem., 43: 1203, 1997.
21. Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Patel, A., Flanigan, R. C., Richie, J. P., deKernion, J. B., Walsh, P. C., Scardino, P. T., Lange, P. H., Herschman, J. D., Subong, E. N. P., Petteway, J. C., Parson, R. E., Loveland, K. G., Gasior, G. H. and Southwick, P. C.: A multicenter clinical trial evaluation of free PSA in the differentiation of prostate cancer from benign disease. J. Urol., part 2, 157: 111, abstract 434, 1997.
22. 1-antichymotrypsin. Clin. Chem., 37: 1618, 1991.
23. Stenman, U. H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhkanen, K. and Alfthan, O.: A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res., 51: 222, 1991.
24. Schröder, F. H.: The TNM classification of prostate cancer. Prostate, suppl., 4: 129, 1992.
25. Brawn, P. N., Ayala, A. G., von Eschenbach, A. H., Hussey, D. H. and Johnson, D. E.: Histologic grading study of prostate adenocarcinoma: the development of a new system and comparison with other methods - a preliminary study. Cancer, 49: 525, 1982.
26. Gleason, D. F.: Histologic grading and staging of prostatic carcinoma. In: Urologic Pathology: The Prostate. Edited by M. Tannenbaum. Philadelphia: Lea and Febiger, 171-197, 1977.
27. Gleason, D. F.: Histologic grading of prostate cancer: a perspective. Hum. Path., 23: 273, 1992.
28. Woodrum, D., French, C. and Shamel, L. B.: Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology, suppl., 48: 33, 1996.
29. Chan, D. W., Sokoll, L. J., Jones, K. A., Kelley, C. A., Subong, E. N. P. and Partin, A. W.: Clinical evaluation of two free PSA assays in combination with different total PSA assays. J. Urol., part 2, 157: 112, abstract 435, 1997.
30. Semjonow, A., Oberpenning, F., Brandt, B., Zechel, C., Brandau, W. and Hertle, L.: Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen. Urology, suppl., 48: 10, 1996.
31. Oesterling, J. E., Jacobsen, S. J., Klee, G. G., Pettersson, K., Piironen, T., Abrahamsson, P.-A., Stenman, U.-H., Dowell, B., Lövgren, T. and Lilja, H.: Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J. Urol., 154: 1090, 1995.
32. Bjork, T., Bjartell, A., Abrahamsson, P., Hulkko, S., di Sant'agnese, A. and Lilja, H.: Alpha-1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology, 43: 427, 1994.
33. Carter, H. B., Partin, A. W., Luderer, A. A., Metter, E. J., Landis, P., Chan, D. W., Fozard, J. L. and Pearson, J. D.: Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology, 49: 379, 1997.